synergy nash tirzepatide Post-hoc analysis of SYNERGY-NASH trial reveals key insights on #tirzepatide in #MASH patients ✓ MASH resolution linked to greater weight loss (-16% vs -7%) ✓ Fibrosis improvement associated with better glycemic control SYNERGY-NASH: Tirzepatide, a GIP/GLP-1 RA,

Effects of indigestible carbohydrates in barley on glucose metabolism, appetite and voluntary food intake over 16 h in healthy adults

Food Chem Toxicol 155:112406

Additional benefits include improved blood sugar regulation, enhanced insulin sensitivity, reduced food noise, better metabolic health, and improvements in obesity-related health markers

Clinical trial results also demonstrated that many participants achieved clinically meaningful weight loss milestones: 96.3% achieved at least 5% weight loss 90.1% achieved at least 10% weight loss 78.2% achieved at least 15% weight loss 62.9% achieved at least 20% weight loss The amount of weight you lose will depend on a range of individual factors, including: Your starting body weight Your prescribed Mounjaro dose Following a balanced diet Regular physical activity Your overall health and response to treatment The image below highlights the average weight loss achieved across different Mounjaro doses during clinical studies